Price is the Main Barrier to Wider Use of Papillomavirus Vaccine

At its debut 2 years ago, a vaccine that pre-vents cervical cancer was heralded as a public health breakthrough that could poten-tially save millions of women’s lives. Yet although the vaccine is now given routinely to young girls in the United States and Europe, it hasn’t been deployed in poorer countries, where it could make a bigger difference.